Member Info for Matml74

Sage Health Care lists Simon Bennett as an Executive Director.

https://www.sagehealthcare.com/simonbennett

Also note they are attending JPM conference in Jan.

“AS clearly states that they are wanting the phase 2 fortnightly study to commence early 2024 in the USA, with a view of completing 2 cohorts by june.”

He doesn’t say two cohorts. He clearly says 2 weekly study to complete end of second quarter.

“ You will now be aware that a hostile entity does not need to own a single share in a target company to launch a formal tender offer - which any BoD will be legally compelled to put to shareholders by the terms of the takeover code.”

😂 😂 No one responded because you clearly have no idea what you are talking about.

Companies are not legally required to put an offer to shareholders. A low ball offer by an entity with no significant holding is very easily defendable and would get laughed out the door by the takeover panel.

From the code…… “ Following an approach to the target board, the target will be responsible for making any required announcement unless it has unequivocally rejected any approach (in cases of doubt, the Panel should be consulted).”

AstraZeneca rejected Pfizer’s $100 billion bid and it never became public until 3 months later when Pfizer came clean!

Your idea of a tender offer is even more ridiculous. They very rarely occur in the UK, and generally only when a company is looking to buy back existing stock in the company. Hostile bids in the UK are also extremely rare with regulations protecting target boards.

If a company wants to make an attempt on Avacta at a valuation that the company rejects, the first shareholders will know about it is when the bidder leaks it in the city, and the SP will jump to whatever level the bid at. It will then be in Avacta’s court on how it plays out.

Hostile bid 😂😂😂 No one entity has enough shares to even attempt it. Explain how this hostile bid is going to be structured for you to even get a chance to vote on it?

“This is where innovators become so emotionally attached to their creation they are unable to let it go.”

He didn’t create it he licensed in the Precision chemistry.

AS main failure is to get significant institutional buy in hence the ridiculous volatility. It will continue until this is sorted out. Plenty of AIM companies with strong IP (seeing Machines for example) have large institutional holdings. This needs to change for Avacta and soon. It will be imperative when takeover talks commence to extra maximum value.

Jive, at the presentation yesterday the patient with 65% reduction in tumour volume was on cohort 3 dosage, Chris C said patient had been on trial for “approaching 10 months”. This is well after cohort 3 had completed. This suggests that patient was added to the cohort after it completed!

I have messaged the company about UK trial screening.

It appears patients are being added to the trial after cohort completion.

Science day presentation - cohort 3 had 6 patients.

Yesterday’s presentation - cohort 3 had 8 patients

Science day - cohort 4 had 3 patients

Yesterday’s presentation - cohort 4 had 7 patients

Both cohorts had completed pre science day.

So appears they are adding patients after cohort completion or perhaps as toxicities emerge with patients still on drug.

Anyone aware if this is the case a whether patients in the UK will be able to access the trial under the current 1a cohort doses?

Slide 11 describes this perfectly and this appears completely missed by many yesterday.

Effectively dosing at 160mg/kg every 2 weeks gives the equivalent cumulative dosage that was given during cohort 5 in P1a.

The next 6 months with data emerging from this arm of the trial should be very exciting considering the current efficacy signals that have emerged.

Baffy, Disease surveillance is not a measure of progression to the next cohort.

As per phase 1a, toxicities in first three patients determine progression to next cohort.

1. Minimal grade 3-4 events observed across all cohorts vs. doxorubicin alone.

2. These severe toxicities limit doxorubicin dosing to every 3 weeks, however the reduction severe toxicities in severe toxicity with AVA6000 enables dosing optimisation to every 2 weeks.

3. >80% reduction across all dose levels of the maximal concentration (Cmax) and 40-80% reduction in total exposure (AUC) of released doxorubicin following AVA6000 dosing compared with standard dose doxorubicin.

be wary of ****s like you.

Also the presentation next week is " a detailed review of the AVA6000 clinical trial's Phase 1a data".

Why are you expecting information on commercialisation? The company presented its future plans for its pipeline at the end of September.

Set expectations for a detailed review of data but if expecting more some may be disappointed.

The tender completion date has already been extended twice suggesting that not enough shares have been tendered for the deal to go through.

I expect it fails again tonight and they extend for go back to the drawing board.

Shareholders know they had a higher bidder conditional on pending phase 3 readout so expect they will hold onto their shares and follow BVF’s lead.

Sorry yes you are correct. I was thinking it related to the previous options that got rolled over to 2026.

Targets were set in 2021 prior to war in Ukraine, inflation going through the roof and interest rates being hiked to highest levels in over a decade. Hopefully coming out the other side of that but unlikely in time to help with PM's options...... unless he can find a buyer.

Notified tonight 11pm CET on msci website.

Ok fair enough. I remember Chris in particular commenting. He is Study Chief Investigator whether he is sitting in the audience or not!

"Just for the record much as we’d like Tap, Twelves or Banerji to comment I don’t believe they are allowed to comment on ongoing trials."

Yet they made numerous comments about the trial at Science day!

It will be published via an rns like all listed companies do when initially announcing trial results.

"Needs to be in general news and media outlets as transforming chemotherapy with no I'll health effects."

Statements like this need to be tempered. Toxicities have been experienced by patients on the trial and to grade 3 level in some cases. The data is all on the SD deck.

The most important consideration though is there has been NO incidence of caridiotxicity which as we all know is the limiting factor in using doxorubicin as a treatment.

I wouldn’t trust any research Redeye put together on any company having downgraded Smarteye’s auto revenue 2 days before earnings call and then on the day state that Smarteye hit their revenue target. What a bunch of amateurs.

Oh………… and their most recent slaying of the Magna mirror when that product has won the largest DMS award to date.